PUBLISHER: Grand View Research | PRODUCT CODE: 1300983
PUBLISHER: Grand View Research | PRODUCT CODE: 1300983
The Asia Pacific predictive disease analytics market size is expected to reach USD 2448.46 million by 2030, registering a CAGR of 24.0% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising pressure of increasing healthcare costs and reduced patient engagement and retention. Moreover, rising investment for technological development in this space by prominent players is driving the market growth. Furthermore, major players, such as IBM Corp., Verisk Analytics, Inc., McKesson Corp., SAS Institute, Inc., Cotiviti, Inc., Optum, Inc., MedeAnalytics, Inc., and Oracle Corp., are undertaking various strategies, such as partnerships, acquisitions, collaborations, product launches, and expansions.
For instance, in April 2022, SAS Institute, Inc. and Microsoft collaborated to build deep technology integrations to make advanced healthcare analytics accessible. This collaboration would enable the use of Fast Healthcare Interoperability Resources by integrating Azure Health Data Services into SAS Health. In December 2020, McKesson Corp. launched an oncology technology and insights business, Ontada. This helped the company advance cancer research and care. Moreover, government support in the form of funding and initiatives will drive the market over the forecast period. According to a study conducted by the Asian Development Bank in August 2022, the adoption of remote patient monitoring and predictive analytics can contribute an estimated USD 9.4 billion and USD 15.5 billion, respectively to the gross domestic product across Southeast Asia by 2030.